Russell Investments Group, Ltd. Aeglea Bio Therapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	SELL	$0.5 - $2.66 $1,504 - $8,001	-3,008 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$6.03 - $7.95 $126,792 - $167,164	-21,027 Reduced 87.48%	3,008 $23,000
Q2 2021 Aug 04, 2021	SELL	$6.32 - $8.38 $382,018 - $506,537	-60,446 Reduced 71.55%	24,035 $165,000
Q1 2021 May 10, 2021	SELL	$6.76 - $8.57 $382,149 - $484,470	-56,531 Reduced 40.09%	84,481 $668,000
Q4 2020 Feb 08, 2021	SELL	$7.02 - $9.83 $172,067 - $240,943	-24,511 Reduced 14.81%	141,012 $1.11 Million
Q3 2020 Nov 09, 2020	BUY	$6.51 - $9.33 $652,054 - $934,511	100,162 Added 153.24%	165,523 $1.17 Million
Q2 2020 Aug 05, 2020	BUY	$4.01 - $11.04 $11,432 - $31,475	2,851 Added 4.56%	65,361 $603,000
Q1 2020 May 06, 2020	SELL	$3.51 - $8.48 $315,327 - $761,817	-89,837 Reduced 58.97%	62,510 $290,000
Q3 2019 Nov 01, 2019	BUY	$6.42 - $9.0 $975,499 - $1.37 Million	151,947 Added 37986.75%	152,347 $1.17 Million
Q2 2019 Aug 09, 2019	BUY	$6.1 - $8.78 $2,440 - $3,511	400 New	400 $3,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.